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ABSTRACT
The Patient Protection and Affordable Care Act is most well-known for creating a mandate requiring
individuals to have health insurance. However, another provision of the Act, the Biologics Price
Competition and Innovation Act, created a new process for companies to introduce biosimilars,
products that are highly similar to licensed drugs in terms of purity, safety, and potency, but have
minor differences in the inactive ingredients. This provision seeks to alleviate strain on companies
introducing biosimilars by creating an abbreviated pathway for their approval by the Food and Drug
Administration, similar to an Abbreviated New Drug Application under the Hatch-Waxman Act.
This article provides a comprehensive overview of the Biologics Price Competition and Innovation
Act and contrasts it with the Hatch-Waxman Act and European Law on Biosimilars. Strategies for
patent claiming and resolving patent disputes are then discussed.
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BIOSIMILARS AND ITS IMPLICATIONS
SHAWN P. GORMAN, ADRIAN PISHKO,
JOHN IWANICKI & JUDITH STONE-HULSLANDER*
INTRODUCTION
On March 23, 2010, the Patient Protection and Affordable Care Act (“Affordable
Care Act”)1 was officially signed into law, which included provisions that greatly
altered the delivery of healthcare services in the United States. The Affordable Care
Act quickly became the center of a national debate as challenges regarding the
constitutionality of certain provisions surfaced.2 A key provision, which became
known as the individual mandate, required citizens to either maintain “minimum
essential” health insurance coverage or pay a fine. 3 This provision was at the heart
of efforts to render the Affordable Care Act unconstitutional and was ultimately
reviewed by the Supreme Court of the United States. 4 Many believed that if the
individual mandate was deemed unconstitutional, the entire Affordable Care Act
would fall, thus negating the provisions entirely unrelated to the individual mandate,
including provisions that related to the regulation of biologics. 5 Indeed, unbeknownst
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University of Florida and earned his Juris Doctor from the Franklin Pierce Law Center. His
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The authors gratefully acknowledge the insights and assistance of Lisa Hemmendinger as well
as the editorial staff of The John Marshall Review of Intellectual Property Law, namely Dawn David
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1 Patient Protection and Affordable Care Act, Pub. L. No. 111-148, 124 Stat. 119 (2010).
2 See Health Care Reform and the Supreme Court (Affordable Care Act), N.Y. TIMES,
http://topics.nytimes.com/top/reference/timestopics/organizations/s/supreme_court/affordable_care_a
ct/index.html (last updated Dec. 6, 2012).
3 26 U.S.C. § 5000A(b)(1) (2012).
4 Nat’l. Fed’n of Indep. Bus. v. Sebelius, 132 S. Ct. 2566 (2012).
5 Supreme Court Health-Care Decision: 3 Scenarios, WASH. POST. (June 21, 2012), http://www.
washingtonpost.com/wp-srv/special/politics/health-care-decision/three-scenarios/index.html.
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to many individuals outside of the Biotechnology industry, the Affordable Care Act
included the Biologics Price Competition and Innovation Act of 2009 (“Biosimilar Act”
or “the Act”).6
On June 22, 2012, the Supreme Court held that the individual mandate and
provision were constitutional, thereby preserving the Healthcare Act, including the
Biosimilar Act.7 This Article discusses key provisions of the Biosimilar Act, including
the newly-created abbreviated approval pathway for biologics. The pathway’s
requirements, such as demonstrating biosimilarity or interchangeability, and the
exclusivities granted under law will also be discussed. The proposed process and
structure of the pathway will be compared and contrasted with the Hatch-Waxman
Act, which addresses the abbreviated pathways for generic drugs, and the current
abbreviated approval processes for biologics in Europe. Lastly, this article discusses
implications for patenting biosimilar inventions and resolving patenting disputes.
I. REGULATION OF BIOLOGICS
A. General Principles
The last several decades produced great advances in the understanding of
biological systems.8 This understanding led to the birth of the biotechnology
industry, which provided a multitude of scientific advancements and innovations.9
Like any radical shift or advancement, however, regulations relating to these
advancements required frequent, and sometimes highly-contested, government
interventions.10 These interventions have come in the form of clarifying existing laws
as well as forming new laws and regulations. Indeed, it was only about thirty years
ago that the Supreme Court was tasked with determining whether human-made
microorganisms were eligible for patent protection, 11 and the term “biotechnology”
was not universally defined until about twenty years ago.12 Since its infancy, the
See Patient Protection and Affordable Care Act, Pub. L. No. 111-148, §§ 7001–03, 124 Stat.
119, 804–21 (2010) (codified as amended in scattered sections of 21 and 42 U.S.C.). The Biologics
Price Competition and Innovation Act of 2009 is Title VII, Subtitle A of the Affordable Care Act. Id.
§ 7001, 124 Stat. at 804.
7 Nat’l. Fed’n Of Indep. Bus., 132 S. Ct. at 2608. The Court determined that another provision
of the Act was unconstitutional, however, and deemed it severable from the Act. Id. at 2607–08.
8 NAT’L INST. OF STANDARDS AND TECH., U.S. DEP’T OF COMMERCE, MEASUREMENT
CHALLENGES TO INNOVATION IN THE BIOSCIENCES: CRITICAL ROLES FOR NIST 1 (2009).
9 Whitney Tiedemann, First-to-File: Promoting the Goals of the United Stated Patent System
as Demonstrated Through the Biotechnology Industry, 41 U.S.F. L. REV. 477, 483 (2007).
10 See, e.g., U.S. DEP’T OF AGRIC., BIOTECHNOLOGY REGULATORY SERVICES: COORDINATED
FRAMEWORK FOR THE REGULATION OF BIOTECHNOLOGY 3 (2006) (explaining the federal
government’s role in creating regulations in the beginning stages of biotechnology).
11 Diamond v. Chakrabarty, 447 U.S. 303 (1980).
12 See, e.g., U.N. Convention on Biological Diversity art. 2, June 5, 1992, 1760 U.N.T.S. 79; 31
I.L.M. 818. The United Nations and the World Health Organization each accepted the 1992
Convention on Biological Diversity (Convention). The Convention defined biotechnology as “any
technological application that uses biological systems, living organisms, or derivatives thereof, to
make or modify products and processes for specific use.” Id.
6
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biotechnology industry has developed an array of therapeutic and medicinal
products.13 Given the less-predictable nature of biologics as compared to traditional
medicines, however, the development, manufacture, and administration of biologic
products to the public in a safe and effective manner have been associated with slow
development phases and high treatment costs. 14
The Biosimilar Act aims to balance the public policy of ensuring the availability
of affordable medicinal and therapeutic biologics against the competing, but equally
important, considerations of the intense investment and risk required to develop and
manufacture effective and safe biologic products. 15
B. Biological Substances Within the Act’s Scope
Most biological products receive regulatory approval in the form of a biologics
license application (“BLA”) under section 351 of the Public Health Service Act.16
Prior to the Biosimilar Act, follow-on biosimilar products seeking regulatory approval
under the Public Health Service Act were required to submit a regular approval
application under section 351(a) in order to obtain licensure from the Food and Drug
Administration (“FDA”).17 Thus, regardless of any similarity, biosimilar applicants
were required to undergo the same licensing guidelines as were required to market
an entirely new and different biologic product in the United States (commonly
referred to as “innovator products”) for which they were modeled after.18
Under the Act, developers of a “biosimilar” product (or inclusive
“interchangeable” product) retain the option to request abbreviated approval by the
FDA.19 Not every substance comprising biological materials is subject to the
provisions of the Biosimilar Act. As indicated above, not all biologic products are
licensed under the Public Health Service Act, which defines “biologics” as:
a virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component
or derivative, allergenic product, protein (except any chemically synthesized
polypeptide), or analogous product, or arsphenamine or derivative of
arsphenamine (or any other trivalent organic arsenic compound), applicable

13 See Jean-Louis Prugnaud, Similarity of Biotechnology-Derived Medicinal Products: Specific
Problems and New Regulatory Framework, 65 BRIT. J. CLINICAL PHARMACOLOGY 619, 619 (2008).
14 FOOD & DRUG ADMIN., U.S. DEP’T OF HEALTH & HUMAN SERVS., CHALLENGE AND
OPPORTUNITY ON THE CRITICAL PATH TO NEW MEDICAL TECHNOLOGIES, at i (2004).
15 Joanna T. Brougher & David A. Fazzolare, Will the Biosimilars Act Encourage
Manufacturers to Bring Biosimilars to Market?, FOOD & DRUG POL’Y F., Mar. 9, 2011, at 1, 5. In
2011, the average cost for a biologic therapeutic or medicinal product in the US was estimated at
$16,000 annually with some costing $120,000. ANDREW F. BOURGOIN, WHAT YOU NEED TO KNOW
ABOUT THE FOLLOW-ON BIOLOGIC MARKET IN THE U.S.: IMPLICATIONS, STRATEGIES, AND IMPACT 1
(2011), available at http://thomsonreuters.com/content/science/pdf/ls/newport-biologics.pdf.
16 42 U.S.C. § 262(a) (2012); see also 21 C.F.R. 601.2 (2013).
17 James V. DeGiulio, FDA Guidance Uncertainty May Deter Use of Abbreviated Biosimilar
Approval Pathway, 6 LIFE SCI. L. & INDUSTRY REP. 467, 467 (2012).
18 Id.
19 Id.
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to the prevention, treatment, or cure of a disease or condition of human
beings.20
Some proteins, however, such as insulin and human growth hormones, are
subject to approval under section 505 of the Federal Food, Drug, and Cosmetic Act
(“FD&C Act”).21 In this regard, the Biosimilar Act is unclear exactly as to the
definite boundaries of what will be deemed a “protein,” “peptide,” or a “chemicallysynthesized polypeptide.”22 The FDA, which is the governmental agency tasked with
reviewing the biologics license applications, has provided guidance documents on the
categorization of biological substances.23 These documents provide guidance as to
how the FDA intends to categorize many substances, including those provided below
in Table 1. Using the FDA’s guidance, Table 1 also provides clarification of whether
the product would be licensed as a biological product under the Public Health Service
Act or as a drug under the FD&C Act.24
Table 1. Definitions of Key Biologic Substances and Implicated Licensure
Polymer

Defined As

Protein

More than 40 amino acids
Specific, defined sequence

Biological product after 3/23/2020
Peptide

40 or fewer amino acids

Drug unless also a biological product
(e.g., vaccine, blood product)
Chemically synthesized polypeptide
Drug unless also a biological product
(e.g., vaccine, blood product)

Fewer than 100 amino acids
Entirely synthetic

42 U.S.C. § 262(i)(1).
Frequently Asked Questions About Therapeutic Biological Products, U.S. FOOD & DRUG
ADMIN.,
http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedand
Approved/ApprovalApplications/TherapeuticBiologicApplications/ucm113522.htm (last visited Feb.
12, 2013); 21 U.S.C. § 355 (2012).
22 See 42 U.S.C. § 262(i)(1) (explaining that the definition of “biological product” includes
“protein,” but excludes “chemically synthesized polypeptide,” and none of these terms are defined
within the Act).
23 Guidance for Industry on Biosimilars: Q&As Regarding Implementation of the BPCI Act of
2009: Questions and Answers Part II, FOOD & DRUG ADMIN., http://www.fda.gov/Drugs/Guidance
ComplianceRegulatoryInformation/Guidances/ucm271790.htm (last updated Feb. 9, 2012). The
FDA has issued draft guidance documents relating to: (1) Scientific Considerations; (2) Quality
Considerations; and (3) Q&A. Id.
24 Id.
20
21
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As shown in Table 1, substances categorized as proteins will be deemed
“biological products” after March 23, 2020.25 Until then, proteins (as currently
defined by the FDA’s guidance documents) will not be required to be submitted under
section 351 of the Public Health Service Act, but may instead be submitted as a drug
under the FD&C Act, subject to certain criteria.26 During the transition period, it
generally depends if there was already another protein in the same product class that
was approved as a drug (but could be used as a reference product) for the protein.
C. Abbreviated Approval Process for Follow-On Products
1. Introduction
The most significant change made by the Biosimilar Act is the creation of an
abbreviated approval scheme for follow-on biologics shown to be biosimilar with an
approved reference product.27 In this regard, the Biosimilar Act is the corollary to
the Hatch-Waxman Act, which established abbreviated pathways for the approval of
generic drug products in the United States.28 Familiarity with the Hatch-Waxman
Act, however, provides little guidance with the Biosimilar Act. Many of the
differences between the two Acts stem from the natural differences between biologics
and traditional drugs. As one example, biologics often come from diverse living
sources, and thus, there is an increased chance of transmitting diseases and agents,
including bacteria and viruses.29 This lends itself to a legal framework having more
validation and controls.
Biologics are also more sensitive to environmental
conditions; therefore, more stringent production and distribution facilities are
required.30 Given the organic nature of biologics, however, most traditional
sterilization techniques are not viable options.31
Id.
See 42 U.S.C. § 355 (2012) (identifying application requirements for the safety and
effectiveness “of the drug or biological product”) (emphasis added); Donna M. Gitter, Innovators and
Imitators: An Analysis of Proposed Legislation Implementing an Abbreviated Pathway for FollowOn Biologics in the United States, 35 FLA. ST. U. L. REV. 555, 563–64 (2008) (“Most biologics,
however, are approved for marketing under provisions of the Public Health Service Act (PHSA).
Because biologics typically meet the definition of ‘drugs‘ under the FDCA, they are governed by that
statute as well.”). This transition period is described in the Affordable Care Act. See Patient
Protection and Affordable Care Act, Pub. L. No. 111-148, § 7002(e), 124 Stat 119, 817 (2010).
27 See Patient Protection and Affordable Care Act, Pub. L. No. 111-148, § 7002, 124 Stat. 119,
804–08 (2010) (codified as amended at 42 U.S.C. § 262(k)). The Act sets forth a heightened standard
of “interchangeable,” id., which will be described in greater detail below.
28 The Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. 98-417, 98
Stat. 1585 (codified as amended in scattered sections of 21 U.S.C.). The Hatch-Waxman Act is
formally known as the Drug Price Competition and Patent Term Restoration Act of 1984.
29 See, e.g., The Basics of Biologics, ARTHRITIS TODAY, Jan.–Feb. 2013, at 56, 57 (discussing the
risks of biologics).
30 Am. Pharmacist Ass’n, The Biosimilar Pathway: Where Will It Lead Us?, PHARMACY TODAY,
Dec. 2011, at 67, 68; Gitter, supra note 26, at 564 (citing commentators’ statements: “[R]egulation
[of biologics] is focused on ‘rigid control of the manufacturing process,’ which reflects the particular
scientific and historical characteristics of biopharmaceuticals”). A biologic license application must
25
26
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The abbreviated approval scheme requires the filing of a biosimilars application
under an entirely new sub-section—section 351(k)—of the Public Health Service Act
that was created through the Affordable Care Act. 32 Given the creation of the new
subsection, these abbreviated applications are commonly referred to as “351(k)
applications,” including throughout this article.
2. Key Definitions of a Biosimilars Application – “351(k) application”
The Affordable Care Act amended section 351 of the Public Health Services Act to
include new subsection (k) which sets forth the requirements for licensing biological
products as biosimilar to a reference product.33 Fortunately, the Biosimilar Act
specifically addresses what constitutes biosimilarity and defines qualifying reference
products.34
Each biologic product seeking expedited approval under 351(k) is compared, and
ultimately judged against, a prior-approved biologic product that was licensed under
the full approval process.35 This “reference product” serves as a standard for safety,
purity, and potency.36 An important issue for many biosimilar applicants is the
Biosimilar Act’s requirement that the prior-approved reference product be a “single
product.”37 Thus, the abbreviated process cannot be used for so-called combination
biologics that consist of multiple biologics. Even if an applicant can successfully
demonstrate that a combination biologic is merely a safe combination of two priorapproved biologic products, approval for any combination products will have to be
sought through the regular approval process.
The Biosimilar Act further requires that the proposed biologic seeking expedited
approval be “biosimilar” to the reference product. As set forth in the Act:
The term “biosimilar” or “biosimilarity”, in reference to a biological product
that is the subject of an application under subsection (k), means—

demonstrate:
(1) the standards regarding safety, purity, and potency are met; (2) the
manufacturing, processing, packaging, and/or holding facility meets certain standards to ensure the
product’s safety, purity, and potency are maintained; and (3) the applicant must allow FDA to
inspect the aforementioned facility. Gitter, supra note 26, at 574.
31 See Daphne Allen, Sterilization: Using Radiation on EtO for Biologics, PMPNEWS.COM (May
29, 2008), http://www.pmpnews.com/article/sterilization-using-radiation-or-eto-biologics (discussing
how biologics cannot generally survive the same sterilization processes which other drugs may).
32 DeGiulio, supra note 17, at 467.
33 Patient Protection and Affordable Care Act, Pub. L. No. 111-148, § 7002, 124 Stat. 119, 804–
08 (2010) (codified as amended at 42 U.S.C. § 262(k) (2012)). Applicants must also demonstrate
(1) the same mechanism of action as the reference product (if it is known), (2) demonstrate the
condition(s) of use previously approved for the reference product, (3) utilize the same route of
administration, dosage form, strength as reference product, and (4) ensure the proposed product
must be manufactured, processed, packed, or held in a facility that meets standards for maintaining
safety, purity, and potency. Id.
34 42 U.S.C. §§ 262(i)(2), (4).
35 See id. § 262(i)(3).
36 See id. § 262(i)(2)(B).
37 Id. § 262(i)(4).
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(A) that the biological product is highly similar to the reference product
notwithstanding minor differences in clinically inactive components; and
(B) there are no clinically meaningful differences between the biological
product and the reference product in terms of the safety, purity, and potency
of the product.38
3. Demonstrating Biosimilarity
The Act further sets forth that biosimilarity is proved through (1) analytical
studies that demonstrate the highly similar features, as compared to the reference
product; (2) animal studies, including the assessment of toxicity, and (3) one or more
clinical studies that are sufficient to demonstrate safety, purity, and potency.39
The Act was written with the correct perspective that biological products are, by
nature, more variable in their properties than traditional drugs, and as such, require
a more flexible framework for establishing biosimilarity. An example of this is
readily shown by the third requirement, which focuses on the clinical studies for
approval. This section requires “a clinical study or studies [that include the]
assessment of immunogenicity and pharmacokinetics or pharmacodynamics.”40 The
Act further specifies that a study or studies must be “sufficient to demonstrate
safety, purity, and potency in 1 or more appropriate conditions of use for which the
reference product is licensed and intended to be used and for which licensure is
sought for the biological product.”41
a. FDA Draft Guidance Documents
The FDA has issued three draft guidance documents to assist applicants with
the process of preparing and submitting an application for a proposed biosimilar
product:




Scientific Considerations
Quality Considerations
Q&A42

The FDA opened a comment phase for the draft guidance documents, which is
now complete; however, to date, no final guidance documents have been issued by the

Id. § 262(i)(2) (emphasis added).
42 U.S.C. § 262(k)(2)(A)(i)(I) (2012).
40 42 U.S.C. § 262(k)(2)(A)(I)(cc) (emphasis added).
41 Id.
42 Fact Sheet:
Issuance of Guidances on Biosimilar Product Development, FOOD & DRUG
ADMIN.,
http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedand
Approved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/ucm291197.htm (last
updated Feb. 9, 2012).
38
39
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FDA.43 Importantly, the FDA guidance documents may indicate that a certain
product class is ineligible for approval for a license due to science and experience
with the particular product class, although the guidance documents may later be
modified or reversed.44
i. Step-Wise Approach
Unlike many government approval processes, including those for seeking drug
approval, the FDA draft guidance document pertaining to scientific considerations
advocates a “stepwise approach” for demonstrating biosimilarity between the
reference product and the biosimilar applicant. 45 Thus, the FDA may, at its
discretion, determine whether any of the comparisons are unnecessary and
recommend presenting development plans and a milestone schedule. 46 The FDA will
provide feedback on a case-by-case basis.47
The FDA recommends beginning with structural and functional characterization
of both products.48 Depending on the outcome of these initial studies (and laterconducted studies), applicants would likely need to provide less data for easily
characterized biological products. Similarly, the FDA’s scientific guidelines make
concessions for the unknown and highly variable nature of biologics with the
“stepwise approach,” which acknowledges that many product-specific factors can
influence a product development program.49 Thus, the assessment of one element
may influence decisions about relevant data for the next step, and the extent of
uncertainty of the biosimilarity may be evaluated to select the next steps to address
that uncertainty.50 Therefore, it is believed that applicants that meet with the FDA
throughout the process (such as ensuring the data conveys an understanding of the
mechanism(s) of action and the safety risks of the reference product) could expedite
completion of the required comparative evidence.

43 Guidance for Industry on Biosimilars: Q & As Regarding Implementation of the BPCI Act of
2009, FOOD & DRUG ADMIN., http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/
Guidances/ucm259797.htm (last updated Mar. 22, 2012); FDA Issues Draft Guidance on Biosimilar
Product Development, FOOD & DRUG ADMIN., http://www.fda.gov/newsevents/newsroom/press
announcements/ucm291232.htm (last updated Feb. 9, 2012).
44 See FOOD & DRUG ADMIN., U.S. DEP’T OF HEALTH & HUMAN SERVS., GUIDANCE FOR
INDUSTRY: SCIENTIFIC CONSIDERATIONS IN DEMONSTRATING BIOSIMILARITY TO A REFERENCE
PRODUCT 1 (2012) [hereinafter SCIENTIFIC CONSIDERATIONS IN DEMONSTRATING BIOSIMILARITY].
45 Id. at 7–8. According to the FDA, the products would be compared with regard to: structure,
function, effectiveness, human pharmacokinetics (PK), human pharmacodynamics (PD), clinical
safety, clinical immunogenicity, and animal toxicity. Id. at 2.
46 Id. at 4.
47 Deborah L. Lu, Draft Biosimilars Approval Guidelines Released by FDA: More Questions
than Answers?, NAT’L L. REV. (Apr. 12, 2012), http://www.natlawreview.com/article/draftbiosimilars-approval-guideline-released-fda-more-questions-answers.
48 SCIENTIFIC CONSIDERATIONS IN DEMONSTRATING BIOSIMILARITY, supra note 44, at 7. The
functional characterization studies include (1) fingerprint, which is the quantification of various
product attributes and (2) the extent of characterization related to the need for studies.
49 Id.
50 Id.

[12:322 2013]
The Biosimilars Act
The United States’ Entry into Regulating Biosimilars and its Implications

331

It is worth noting that the biological product needs to be shown to be “biosimilar”
(or interchangeable) and not superior to the reference product for which it is being
evaluated.51 Thus, clinical studies need to demonstrate that a proposed biologic
product has neither decreased nor increased activity compared to the reference
product.52 For example, increased activity of a biologic product may mean more
adverse side effects, which would preclude being considered biolsimilar. Further, if
the increased activity results in a superior product (e.g., improved efficacy), it may
result in the FDA treating the biologic as a new product with superior efficacy (e.g.,
under section 351(a) of the Public Health Service Act).53 Conversely, if the studies
demonstrate decreased activity, as compared to the reference product, this would also
preclude a proposed biologic product from being “biosimilar” and thus a successful
licensure of the proposed product.54 Therefore, only proposed products with the same
activity are subject to licensing as biosimilar products. 55
ii. Totality of the Evidence
The FDA further advocates a “totality-of-the-evidence approach” in licensing
biologics.56 Similar to the “stepwise approach,” the totality approach appreciates the
great variations in proteins, and thus the requisite approval process. 57 This riskbased approach foregoes rigid requirements for specific types of comparative data,58
but instead looks for any clinically meaningful differences with respect to each of the
following:
safety, purity, and potency.59
Thus, the “totality-of-the-evidence”
determination will likely be informed by FDA input during the stepwise approach. 60
The FDA documents further address the impact of specific protein product
complexity.61 In this regard, it is understood that the biologic product being applied
for is likely not structurally identical to the reference product. Indeed, protein
modifications and higher order structure may be affected by environmental
conditions, including those inherent in the manufacturing process itself. 62 As it is
known in the biological sciences, structure dictates (or at least greatly affects)
function, and thus, minor structural differences may have significant effects on
safety, purity, and potency.63 Therefore, an applicant may have to provide more
Id. at 17.
Id.
53 Id.
54 Id.
55 Id. at 8.
56 Id. at 8.
57 Id. at 2.
58 See FOOD & DRUG ADMIN., U.S. DEP’T OF HEALTH & HUMAN SERVS., GUIDANCE FOR
INDUSTRY: PROVIDING CLINICAL EVIDENCE OF EFFECTIVENESS FOR HUMAN DRUG AND BIOLOGICAL
PRODUCTS 3 (1998) (referring to substantial evidence as “adequate and well-controlled
investigations, including clinical investigations, by experts”).
59 SCIENTIFIC CONSIDERATIONS IN DEMONSTRATING BIOSIMILARITY, supra note 44, at 8.
60 Id. at 21.
61 Id. at 4–5.
62 Id. at 5.
63 Id. at 4.
51
52
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extensive data from analytical, animal, and clinical studies when analytical
methodology is incapable of detecting relevant differences between two proteins. 64
1. Implications
From a legal perspective, the step-wise/totality-of-the-evidence approach poses
some serious strategy considerations and raises possible concerns regarding the
examination of these applications. The step-wise approach is based upon the total
evidence.65 In this regard, each 351(k) application for a biosimilar product must
stand on its own.66 Specifically, FDA approval of a 351(k) application must be based
upon data in the 351(k) application and any publicly available information that may
be available regarding the reference product from which the applied-for biosimilar is
modeled.67 The distinction of publically available information is an important one.
Trade secrets submitted by innovators as part of a BLA license, under the full nonabbreviated process for the “reference product” for the biosimilar, are protected from
public disclosure.68 Thus, the biosimilar applicant cannot rely on these trade secrets.
The guidelines for trade secret protection, however, are still being finalized. 69 In
this regard, it is common for government agents or employees, most familiar with
specific technology, to be assigned to analyze technical applications from
competitors.70 For example, patent examiners at the United States Patent and
Trademark Office (“USPTO”) are assigned to Art Groups.71 Art Groups are formed
according to technological boundaries. 72 As such, patent examiners in a single Art
Group, or even closely related Art Groups, routinely examine patent applications
from competitors regarding highly similar subject matter. 73
Therefore, questions regarding the FDA’s examination process and assignment
of reviewers to the BLAs are natural and logical. For example, will 351(k) reviewers
also review the “reference product’s” trade secrets? From an efficiency perspective,
such reviewers may be best suited to fully understand the technology and the various
issues, which will ensure that safety, potency, and purity are addressed. 74 Would
Id. at 8–10.
Id. at 21.
66 Id. at 3–4.
67 Id. at 4.
68 Richard A. Epstein, The Constitutional Protection of Trade Secrets and Patents Under the
Biologics Price Competition and Innovation Act of 2009, 66 FOOD & DRUG L.J. 285, 289 (2011).
69 See Krista H. Carver et al., An Unofficial Legislative History of the Biologics Price
Competition and Innovation Act of 2009, 65 FOOD & DRUG L.J. 671, 756 (2012).
70 See, e.g., IAIN M. COCKBURN ET, AL, ARE ALL PATENT EXAMINERS EQUAL? EXAMINERS,
PATENT CHARACTERISTICS, AND LITIGATION OUTCOMES 5 (2002) (explaining how patent applications
are assigned to examiners).
71 Id.
72 See id.
73 See ANNEMARIE L. M. FIELD ET AL., PATENT EXAMINER RECRUITMENT: AN INTERACTIVE
QUALIFYING PROJECT FOR THE USPTO 81 (2007), available at http://www.wpi.edu/Pubs/Eproject/Available/E-project-121207-102952/unrestricted/USPTOFINALREPORT.pdf.
74 Cf. Id. (explaining how patent examiners become “experts in [their] field” by working with
one type of technology).
64
65
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this, however, result in improper reliance? For example, would such review
processes result in inadvertent reliance on an innovator’s trade secrets regarding the
reference product? Even if the FDA reviewer did not explicitly disclose the trade
secrets, could they be inferred in the reviewer’s acceptance of limited data or
otherwise forego the need for different or additional tests?
In April 2012, Abbott Laboratories (“Abbott”) submitted a Citizen Petition75
requesting that the Commissioner of the FDA confirm that it will not take any action
with respect to a biosimilar application that cites, as its reference product, “Abbott’s
BLA 125057 for Humira (adalimumab) or any other product for which the biologics
license application (BLA) was submitted to the FDA prior to March 23, 2010, the date
on which the [Act] was signed into law.”76 According to Abbott, it:
had no notice, or reasonable expectation, that the agency would use its
trade secrets to approve another company’s product[, and in fact, had]
developed and submitted those trade secrets in reasonable reliance on
FDA’s lack of legal authority to approve biosimilars, confirmed by years of
agency statements that it lacked such authority.77
In May 2012, the FDA solicited comments via a public daylong meeting in which
others voiced concerns over the need for safeguards to protect inadvertent trade
secret disclosure.78
An increased risk of trade secret exposure may warrant greater reliance of
patent protection for innovations that may be novel and non-obvious.79 This,
however, may not be a viable option for those innovations where it is hard to
demonstrate infringement—such as manufacturing processes conducted within a
competitor’s factory.80 This is also not a feasible option for those applications for
which foreign protection is sought, given the fact that a foreign filing license requires
a Request for Non-Publication to be rescinded within a relatively early timeframe.81

75 Letter from Covington & Burling LLP, on behalf of Abbott Laboratories, to Commissioner of
Food and Drugs (Apr. 2, 2012), available at http://patentdocs.typepad.com/files/abbotts-citizenpetition.pdf. The Petition was submitted under 21 C.F.R. 10.30 and section 351 of the Public Health
Service Act (as amended by the Act). Id.
76 Id.
77 Id.
78 Draft Guidances Relating to the Development of Biosimilar Products; Public Hearing;
Request for Comments, FOOD & DRUG ADMIN., http://www.fda.gov/Drugs/NewsEvents/ucm265628
.htm (last updated July 6, 2012).
79 See Richard A. Epstein, The Constitutional Protection of Trade Secrets and Patents Under
the Biologics Price Competition and Innovation Act of 2009, 66 FOOD & DRUG L.J. 285, 285–96
(2011), for a great discussion on how the Biosimilars Act implicates trade secrets.
80 The patent laws account for some of the inherent difficulties in demonstrating infringement
in such situations. For example, although plaintiffs ordinarily bear the burden of proving
infringement, “there is a rebuttable presumption [under § 271(g)] that [an] imported product was
made from [a] patented process if the court finds: ‘(1) that a substantial likelihood exists that the
product was made by the patented process, and (2) that the plaintiff has made a reasonable effort to
determine the process actually used in the production of the product and was unable to so
determine.’” Creative Compounds, LLC v. Starmark Labs., 651 F.3d 1303, 1314 (2011).
81 37 C.F.R. § 1.213 (2013).
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These are some of the issues that will need to be resolved before many biologic
product manufacturers will rely on the abbreviated pathway.
2. State of the Art
The best indication of what to expect comes from the FDA’s draft guidance
document regarding Quality Considerations, which indicates the need for relevant,
analytical studies.82 In this regard, not all biologics may be suitable for licensure as
a biosimilar biological product.83 For example, if the state-of-the-art technology
cannot adequately characterize the reference and proposed products, a biosimilarity
application may not be appropriate.84 Another consideration may be that, during
manufacturing, an applicant might aim to target physiochemical and functional
properties of the reference product to increase the possibility of demonstrating that
the products are highly similar.85
Acceptance criteria are based on the totality of the analytical data, and the
FDA’s guidance documents encourage a side-by-side, comparative analysis of the
proposed and reference products across various lots and timeframes. 86 For example,
the FDA’s guidance document related to Quality Considerations recommends
performing a number of analytical studies to establish quality attributes in order to
define the proposed product for comparison to the reference product.87 Analytical
characterization is further essential in designing the product manufacturing process
and development studies to be able to effectively demonstrate biosimilarity of a
proposed product to a reference product.88
The FDA guidance document related to Scientific Considerations addresses
general scientific principles in conducting studies to demonstrate the biosimilarity of
a proposed product.89 In particular, manufacturing process considerations are
discussed because differences in biological systems may affect structure, and thus,
function of a product.90 Variations in any of the cell line, raw materials, equipment,
processes, controls, and acceptance criteria can each contribute to producing a
FOOD & DRUG ADMIN., U.S. DEP’T OF HEALTH & HUMAN SERVS., GUIDANCE FOR INDUSTRY:
QUALITY CONSIDERATIONS IN DEMONSTRATING BIOSIMILARITY TO A REFERENCE PROTEIN PRODUCT 4
(2012) [hereinafter QUALITY CONSIDERATIONS IN DEMONSTRATING BIOSIMILARITY].
83 Id.
84 SCIENTIFIC CONSIDERATIONS IN DEMONSTRATING BIOSIMILARITY, supra note 44, at 10.
85 QUALITY CONSIDERATIONS IN DEMONSTRATING BIOSIMILARITY, supra note 82, at 6.
Analytical procedures would potentially be capable of characterizing each of the following: desired
product, product-related substances, and impurities. Id. With respect to structure, the FDA’s draft
guidance document regarding Scientific Considerations indicates that the expression construct for
the proposed product will encode the same primary amino acid sequence as the reference product,
while minor structural modifications (e.g., N- or C- terminal truncations) should be justified by the
Applicant as not affecting safety or effectiveness. SCIENTIFIC CONSIDERATIONS IN DEMONSTRATING
BIOSIMILARITY, supra note 44, at 9.
86 QUALITY CONSIDERATIONS IN DEMONSTRATING BIOSIMILARITY, supra note 82, at 7.
87 Id. at 6. Quality attributes may include identity, quantity, purity, potency, consistency,
three-dimensional structure, and identification of impurities and product-related substances. Id.
88 Id. at 15.
89 SCIENTIFIC CONSIDERATIONS IN DEMONSTRATING BIOSIMILARITY, supra note 44, at 7.
90 Id. at 5.
82
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biological product that is different from a reference product.91 An applicant seeking
to establish biosimilarity, where the reference product is made by a different
manufacturer, will, therefore, likely need to present more data than a different
process from the same manufacturer to establish biosimilarity of the proposed
product to a reference product. The guidance document recommends a robust
analytical comparison of a proposed product and a reference product, with respect to
a number of structural aspects. 92 Moreover, testing for multiple lot-to-lot variability
of proposed and reference products and of finished dosage forms is also encouraged.93
Consequently, applications for biosimilar licenses may not be appropriate for
biological products that cannot be well characterized analytically.94
Data from a non-U.S. licensed reference product, to compare to a proposed
biosimilar product, may be acceptable, including animal or clinical studies, to meet
part of the scientific requirements.95 To use data from a non-U.S. licensed reference
product, however, the applicant must be able to establish a scientifically relevant
bridge between the non-U.S. licensed reference product and the U.S. licensed
reference product.96
iii. Safety, Purity, Potency
As indicated above and elsewhere in the Affordable Care Act, the determination
of biosimilarity is based upon the three main factors of safety, purity, and potency. 97
Safety refers to the relative freedom from harmful effects, either direct or indirect,
when a product is prudently administered to a recipient. 98 Safety also takes into
consideration the character of the product in relation to the condition of the
recipient.99 Purity refers to the relative freedom from extraneous matter in the
finished product, regardless of whether or not it is harmful to the recipient or
deleterious to the product, including (but not limited to) relative freedom from
residual moisture or other volatile substances and pyrogenic substances. 100 Potency
refers to the specific ability or capacity of a product to yield a given result, which is
indicated by appropriate laboratory tests. 101
The FDA recognizes that certain instances of licensed biosimilar products may
require a post-marketing study to evaluate safety risks. 102 Further, rare safety risks
Id. at 5–6.
Id. at 9. Structural aspects may include primary structures (e.g., amino acid sequence),
higher order structures (e.g., 2°, 3° and 4° structure, aggregation), enzymatic post-translational
modification (e.g., glycosylation and phosphorylation), potential variants (e.g., protein deamidation
and oxidation), intentional chemical modification (e.g., PEGylation sites and characteristics). Id.
93 Id.
94 Id. at 10.
95 Id. at 6.
96 Id.
97 Id. at 8.
98 21 C.F.R. § 600.3(p) (2013).
99 Id.
100 Id. § 600.3(r).
101 Id. § 600.3(s).
102 SCIENTIFIC CONSIDERATIONS IN DEMONSTRATING BIOSIMILARITY, supra note 44, at 20.
91
92
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may be identified in post-marketing monitoring, due to studying a larger population
size than in prior clinical trials.103
Some studies may consider safety and
effectiveness concerns for the use of a reference product and set mechanisms in place
for differentiating between adverse events associated with the proposed product
versus the reference product.
iv. Interchangeability
It is readily conceivable that two different biosimilar candidates could each be
“highly similar” to the same reference product, but less similar with respect to each
other. It is equally conceivable that these same two candidates have “no clinically
meaningful differences . . . [from] the reference product in terms of the safety, purity,
and potency . . . .”104 Thus, each of these two candidates may be considered
biosimilar with respect to the reference product. Nonetheless, one of them may
exhibit a higher degree of similarity with the reference product than the other and as
such, may be a better product. In this regard, the Act recognizes that there are
varying levels of biosimilarity. It further recognizes that there are public policy
reasons to incentivize increased biosimilarity. 105 Thus, the Act encourages the
production of biosimilar products that are “interchangeable.” A biological product is
considered “interchangeable” 106 if:
(A) The biological product—
(i) is biosimilar to the reference product; and
(ii) can be expected to produce the same clinical result as the reference
product in any given patient; and
(B) for a biological product that is administered more than once to an
individual, the risk in terms of safety or diminished efficacy of alternating or
switching between use of the biological product and the reference product is
not greater than the risk of using the reference product without such
alternation or switch.107
The Act further clarifies that a product shown to meet these standards “means
that the biological product may be substituted for the reference product without the
intervention of the health care provider who prescribed the reference product.”108
Id.
42 U.S.C. § 262(i)(2)(B) (2012).
105 See, e.g., Patient Protection and Affordable Care Act, Pub. L. No. 111-148, § 7001(b), 124
Stat. 119, 804 (2010) (“It is the sense of the Senate that a biosimilars pathway balancing innovation
and consumer interests should be established.”).
106 The FDA has not yet established guidance for demonstrating interchangeability of a
proposed product with a reference product.
107 42 U.S.C. § 262(k)(4) (2012) (emphasis added).
108 Id. § 262(i)(3).
103
104
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Thus, a biosimilar deemed interchangeable may be substituted by a pharmacy
without requiring doctor approval.109 Further, in the United States, obtaining
licensure as the first interchangeable biosimilar is conferred with certain exclusivity
rights, which are discussed immediately below. 110
D. Exclusivities
1. Innovator Products
Innovator products, which are the first of their kind (and, as such, may later
serve as a reference product for a biosimilar product), undergo the full licensing
requirements set forth under section 351(a) of the Public Health Service Act.111
Recognizing that such developments require large amounts of risk and capital
investment, the Act grants such innovator products a twelve year period of
exclusivity.112 This exclusory period consists of four years of data exclusivity followed
by eight years of market exclusivity.113 During the four years of data exclusivity,
biosimilar applicants cannot rely on any data submitted by the innovator for
consideration in the licensing of the innovator product.114 In fact, during this time,
no biosimilar applications are even accepted by the FDA. 115 Further, the remaining
eight years of exclusivity (in the form of market exclusivity) ensures that the FDA
cannot approve any biosimilar (or interchangeable) products until twelve years
following the granting of a biologics license to the initial innovator product. 116
An additional six months of exclusivity is given for those innovator products that
are approved for pediatric use.117 If an orphan drug is produced, the exclusivity of
the orphan drug remains either the later of the initial twelve years of the exclusivity
period or seven years after the orphan.118 It is important to note that each of these
exclusivities are with respect to any follow-on biologics that attempt to seek approval
under the abbreviated approval pathway as being “biosimilar” or “interchangeable;”
however, the exclusivities do not apply to any products approved under the full
licensing process under section 351(a).119 Second, the exclusivities do not permit
“evergreening” for a new indication, route, dosing schedule, form, delivery system,
Id.
Id. § 262(k)(6).
111 Id.; see also DeGiulio, supra note 17, at 467 (discussing the two pathways biosimilar
applicants can choose).
112 42 U.S.C. § 262(k)(7)(A).
113 Compare id. § 262(k)(7)(A) (granting twelve years of exclusivity “after the date on which the
reference product was first licensed”), with id. § 262(k)(7)(B) (requiring an applicant to wait “4 years
after the date on which the reference product was first licensed” before an application can be filed).
114 42 U.S.C. § 262(k)(7)(B) (2012).
115 Id.
116 Id. § 262(k)(7)(A).
117 Id. § 262(m)(2)(A).
118 Patient Protection and Affordable Care Act, Pub. L. No. 111-148, § 7002(h), 124 Stat. 119,
821 (2010).
119 Id.
109
110
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device, strength, or change in structure not resulting in a change in safety, purity, or
potency.120
2. Biosimilar/Interchangeable Products
Approval of the first, or any subsequent, biosimilar product based upon a
reference product does not confer any right with respect to exclusivities. The first
approved interchangeable biosimilar product, however, is granted between twelve
and forty-two months of market exclusivity.121
E. European Regulations Regarding Biosimilar Licensing
1. Innovator Products
As indicated above, the FDA is tasked with approving biosimilars in the U.S. 122
The process is yet to be fully defined and tested as the three draft guidance
documents were issued less than a year ago. In the European Union (“EU”), the
process has had a bit more time to develop.123 In this regard, the European
Medicines Agency (“EMA”), the agency tasked with reviewing biosimilar
applications,124 already has numerous guidelines, both drafted and adopted.125 The
general guidelines were published in 2005, and the first biosimilar was approved in
the EU in 2006.126 The EMA routinely issues “Concept Papers” that, among other
things, provide recommendations on amending draft guidelines as well as revising
guidelines.127 Comments often are solicited based upon the Comment Papers. 128
The EMA’s guidelines are similar to the proposed “stepwise approach” set forth
by the FDA’s guidance documents. Specifically:

See Henry Grabowski et al., Implementation of the Biosimilar Pathway: Economic and
Policy Issues, 41 SETON HALL L. REV., 511, 514–15 (2011).
121 42 U.S.C. § 262(k)(6) (2012).
122 Id. § 262(k)(5)(B).
123 Grabowski et al., supra note 120, at 520.
124 Id. These biosimilar applications are referred to as Biosimilar Marketing Authorization
Applications.
125 Id.
126 Eur. Meds. Agency [EMA], Guideline on Similar Biological Medicinal Products, EMEA Doc.
No. CHMP/437/04 (Oct. 30, 2005), available at http://www.emea.europa.eu/docs/en_GB/document_
library/Scientific_guideline/2009/09/WC500003517.pdf.
127 The EMA’s collection of concept papers may be searched online at: http://www.ema.europa.
eu/ema/index.jsp?curl=pages/document_library/landing/document_library_search.jsp&mid= (enter
“concept paper” in the “Search by keyword in title” field; then click “Submit”).
128 See e.g., Comments from the Biotechnology Industry Organization on the ‘Concept Paper on
the Revision of the Guideline on Similar Biological Medicinal Products Containing BiotechnologyDerived Proteins as Active Substance: Non-Clinical and Clinical Issues’, EMA/CHMP/BMWP/
572828/2011 (Dec. 31, 2011), available at http://www.bio.org/sites/default/files/BIO%20Comments
%20to%20EMA%20Concept%20Paper%2031%20Dec%202011.pdf.
120
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If the information required in the case of essentially similar products
(generics) does not permit the demonstration of the similar nature of two
biological medicinal products, additional data, in particular, the
toxicological and clinical profile shall be provided. . . . The type and
amount of additional data . . . shall be determined on a case by case
basis in accordance with relevant scientific guidelines.129
Approval by the EMA follows a Product Class-Specific guidance that looks to the
EU guidelines and Concept Papers.130 To date, there are guidance documents on the
following product classes:
Interferon ß, recombinant interferon α, recombinant follicle stimulation
hormone, monoclonal antibodies, recombinant erythropoietins, lowmolecular-weight heparins, recombinant human insulin, and somatropin 131
Generally, non-clinical in vitro studies are first conducted, which determine
whether a need exists for in vivo studies.132 Clinical studies will generally be
initiated with pharmacokinetics133 and pharmacodynamics,134 followed by studies of
clinical
efficacy,
clinical
safety,
extrapolation
of
indications,
and
pharmacovigilance.135 To date, the EMA has approved fourteen biosimilars. Table 2
provides the biosimilars approved as compared with their respective reference
products.

129 Directive 2001/83, of the European Parliament and of the Council of 6 November 2001 on
the Community Code Relating to Medical Products for Human Use, Annex, 2001 O.J. (L 311) 1, 100
(EC) (emphasis added).
130 Grabowski et al., supra note 120, at 520–21.
131 Multidisciplinary:
Biosimilar, EUR. MEDS. AGENCY, http://www.ema.europa.eu/ema/
index.jsp?curl=pages/regulation/general/general_content_000408.jsp&mid=WC0b01ac058002958c
(last visited Feb. 17, 2013) (listing all guidance documents).
132 EMA, Guideline on Similar Biological Medicinal Products Containing Monoclonal
Antibodies (Draft) at 5, Nov. 18, 2010, EMEA Doc. No. CHMP/BMWP/403543/2010 (2010), available
at http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/11/WC500099
361.pdf.
133 Id. at 6–9 (showing that clinical studies include studying design, sampling times, examining
parameters of interest, and examining timing).
134 Id. at 9 (explaining that markers are used as support, to establish comparability, and can be
used as pivotal proof of comparability).
135 Id. at 9–12.
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Table 2. Biosimilar Products Approved by the EMA 136
Somatropin (Recombinant Human Growth Hormone)
•

Omnitrope powder (somatropin) from Sandoz based on
Pfizer’s Genotropin®

•

Valtropin (somatropin) from Biopartners, based on Lilly’s
Humatrope®

Epoetin alfa and epoetin zeta products based on Janssen-Cilag’s
Eprex/Erypo (EPOs)
•

Binocrit (epoetin alfa) from Sandoz

•

Epoetin Alfa Hexal (epoetin alfa) from Sandoz (Hexal)

•

Abseamed (epoetin alfa) from Medice

•

Silapo (epoetin zeta) from Stada

•

Retacrit (epoetin zeta) from Hospira

Filgrastim products based on Amgen’s Neupogen® (Granulocyte Colony
Stimulating Factor)
•

TevaGrastim (filgrastim) from Teva

•

Ratiograstim (filgrastim) from Ratiopharm

•

Filgrastim ratiopharm (filgrastim) Ratiopharm (now
withdrawn)

•

Biograstim (filgrastim) from CT Arzneimittel

•

Zarzio (filgrastim) from Sandoz

•

Filgrastim Hexal (filgrastim) from Hexal

•

Nivestim (filgrastim) from Hospira UK

2. Exclusivities
In the EU, innovator drugs obtain ten years of exclusivity consisting of an initial
data exclusivity period of eight years, followed by two additional years of market
exclusivity.137 Similar to the U.S. approach, pediatric uses may result in an
additional one-year extension to the market exclusivity (thus providing three years
total market exclusivity).138 Orphan innovator products are provided ten years
136 European Public Assessment Reports, EUR. MEDS. AGENCY, http://www.ema.europa.eu/ema/
(click “Find medicine” tab; then follow “Human medicines” hyperlink; select “Browse by type”; then
select “Biosimilars” radio button; then click “Submit”) (last visited Feb. 17, 2013).
137 Brook K. Baker, Ending Drug Registration Apartheid:
Taming Data Exclusivity and
Patent/Registration Linkage, 34 AM. J.L. & MED. 303, 307–08 (2008).
138 See Commission Regulation 1901/2006, of the European Parliament and of the Council of 12
December 2006 on Medicinal Products for Paediatric Use and Amending Regulation (EEC) No
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market exclusivity, except pediatric orphan innovator products, which are granted
twelve years market exclusivity.139
Market exclusivity may be extended an
additional year if the reference product sponsor obtains approval for a second new
indication during the data exclusivity period. 140 Similar to the U.S., the EU does not
grant exclusivities for biosimilar products.141 Unlike the U.S., however, the EU does
not have a corresponding category for “interchangeable,”142 and as such, there is no
automatic substitution for biologics in the EU.143 Table 3 provides a summary of the
exclusivities discussed thus far.
Table 3. Exclusivities in the European Union and United States
Exclusivity Indication

European Union

United States

Innovator Data Exclusivity

8 years

4 years

Innovator Market
Exclusivity

2 years

8 years

Pediatric Extension

1 year market
exclusivity

6 months

Orphan

10 years market
exclusivity

Later of 12 years or 7
years after approval

Pediatric Orphan

12 years market
exclusivity

Later of 12.5 years or
7.5 years after approval

Innovator Second Indication

If 2nd indication
approved during data
exclusivity, then market
exclusivity is extended 1
year

N/A

Biosimilar Exclusivity

None

None

Interchangeable Exclusivity

None

12–42 months

1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004, art. 36(5),
2006 O.J. (L 378) 1, 13 (EC).
139 Id. art. 37, 2006 O.J. (L 378) 1, 13 (EC).
140 Jonathan Loeb, Comparison of U.S. and European Biosimilar Regulation and Litigation,
BIOLAWGICS (Mar. 29, 2011), http://www.biolawgics.com/fda-approval/comparison-of-us-andeuropean-biosimilar-regulation-and-litigation/.
141 Id.
142 Id.
143 Id.
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II. PATENTING CONSIDERATIONS
A. Introduction / General Principles
Innovators who first discover and seek approval of the innovator biologic product
through the full regulatory approval process clearly would benefit from seeking
coverage broad enough to cover its own product. With the advent of the biosimilar
pathway for mimicking products, innovators must also be sure to consider the
biosimilar landscape. As such, possible design-around options, including methods
that may be less desirable, may be worthy of fully disclosing and claiming. From the
biosimilar applicant’s perspective, the biosimilar product should be designed to avoid
overlapping the innovator’s claim scope; however, alterations to the proposed
biosimilar product cannot result in a molecule that is so changed that it is no longer
biosimilar.
Further, biosimilar applicants have an incentive to seek the
“interchangeable” status for their products to obtain the twelve to forty-two months
of exclusivity.144
B. Combining Exclusivities
There is no requirement for entities to possess exclusionary patent rights in
order to obtain any of the exclusivities set forth by the Biosimilars Act. Nor are there
any maximum limits on overlapping patent rights and exclusivity periods. 145
Therefore, when feasible, it is highly recommended to pursue both patent rights and
exclusivity periods under the Act to preserve multiple options against competitors.
In this regard, each application will be examined by different government agencies
(different fact-finders) and impose different burdens,146 and in the end, will provide
two different potential causes of action against competitors. 147
Patent rights remain important given the limitation of the exclusivity periods
offered by the Biosimilar Act. First, exclusivity may not apply to all “follow on”
products. For example, the twelve-year exclusivity period granted to innovator
products only applies to (and thus blocks) products approved through the abbreviated
biosimilar pathway.148 Thus, a product that is truly “biosimilar” to the innovator
product can be pursued through the regular application pathway, thereby avoiding
the innovator product’s exclusivity restrictions.

42 U.S.C. § 262(k)(6)(A)–(C) (2012).
See Grabowski et al., supra note 120, at 557 (claiming exclusivity provides an “insurance
policy” to the patent system); 35 U.S.C. § 154(a)(2) (granting patent rights for a term of twenty years
from the filing date of the patent application).
146 Compare 35 U.S.C. § 1(a) (establishing USPTO’s authority to grant and issue patent), with
42 U.S.C. § 262(k)(5) (establishing FDA’s authority to review 351(k) applications).
147 Compare 35 U.S.C. § 271 (patent infringement), with 42 U.S.C. § 262 (FDA exclusivity
period).
148 42 U.S.C. § 262(k)(7).
144
145
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C. Patent Claiming Strategies
1. Revised Patent Landscape
On September 8, 2011, the United States Senate approved the Leahy-Smith
America Invents Act (“AIA”),149 finalizing congressional acceptance of the largest
alterations in U.S. patent laws in over half of a century.150 By far the most sweeping
change included in the AIA is the transition from a “first to invent” system to a
modified “first inventor to file” system.151 This change, combined with the provisions
of the Biosimilars Act, creates a tension in striking the balance between conducting
the necessary tests to support a full disclosure that will cover the innovative product
and any biosimilar products against the requirement of being the first to file the
requisite application.152
Clearly, filing before a competitor is a key factor. This early filing, however,
may not contain enough information (or adequately convey the information) to
effectively block biosimilar products and/or protect later-determined commercial
embodiments. This consideration is not limited to innovator products. For example,
a biosimilar product made by novel and non-obvious processes may require efficient
filing strategies to prevent other biosimilar competitors from entering the market
and/or blocking the manufacture of the innovative product with novel processes
and/or materials.153 On the other end of the spectrum, a later filing date (even if
more robust) may cause equally unfavorable outcomes. For innovators, failing to
secure patent rights opens more opportunities for biosimilar products to enter the
market before the costs of research and development can be recouped. 154 Similarly,
any biologics manufacturer, regardless of being an innovator or a biosimilar
manufacturer, can be blocked from selling their product. For example, an innovator
who obtains the twelve-year exclusivity period under the Biosimilar Act may still be
prevented from making or selling their product that has innovator exclusivity
because it is blocked by a competitor’s patent that was earlier filed.155

H.R. 1249, 112th Cong. (2011) (enacted).
Candice Decaire et al., Negotiating a New Legal Landscape: The Advent of Follow-On
Biologics, 46 U.S.F. L. REV. 1029, 1030 (2012).
151 Id.
152 Id. at 1059 (discussing the tension that a “first inventor to file” system causes between
having an adequate written description and time required to perfect biologic molecules).
153 Id.
154 Compare, 35 U.S.C. § 154(a)(2) (2012) (establishing a patent term of twenty years from the
date of application), with 42 U.S.C. § 262(k)(7) (protecting a reference product for only twelve years).
155 See 35 U.S.C. § 271(a) (defining infringement as selling or offer to sell any patented
invention); 35 U.S.C. § 283 (allowing injunctive relief as a remedy for infringement).
149
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2. Claiming Strategies
As explained above, passage of the Biosimilar Act increases the importance of
adequately describing alternative embodiments. 156 This remains true even for
embodiments that may not be directly important to the specific biologic substance.
For example, embodiments of less-commercial importance may still warrant strong
protection. As one example, a specific biologics product may be produced with two
different excipients; however, a second excipient causes manufacturing costs to rise
or otherwise may be less desirable. Despite this second excipient being less
preferred, it still may be an acceptable candidate for use with a biosimilar product.157
Further, although it is currently less preferred at the time of filing the patent
application, it may become more preferable as time passes. This may be due to
results obtained during the regulatory approval process (either the full approval
process or the abbreviated process). For example, safety results may suggest that an
excipient, previously considered the top candidate, is less than ideal. In this regard,
the FDA may require safety tests to be conducted following granting of the biologics
license.158 Other factors, such as external economic forces, may remove or minimize
any disincentives for the second excipient or other ingredient.
Claiming strategies should consider claiming an entire genus as well as one or
more species within the genus. For example, instead of claiming a preferred cell line
(e.g., mammalian, cell line A), consider claiming the genus of “mammalian cell lines.”
This strategy can also be implemented to claim overlapping or alternative ranges.159
This may be advantageous, for example, when reciting cell growth and selection
parameters or purification properties. Another strategy may consider utilizing
“product by process” claims, if appropriate.160 For example, patent applications are
often drafted during the early stages of development. 161 This will continue to be true
in view of the modified first-to-file system imposed under the AIA.162 During these
early stages of development, the biologic substance of interest may not be adequately
characterized. In certain instances, the very nature of the biologic substance may

See also Kate S. Gaudry, Exclusivity Strategies and Opportunities in View of the Biologics
Price Competition and Innovation Act, 66 FOOD & DRUG L.J. 587, 614 (2011) (explaining that “there
are more potential design-arounds for biologics” than for small-molecule drugs, thus demanding
more alternative embodiments).
157 See 42 U.S.C. § 262(i)(2) (2012) (allowing “minor differences in clinically inactive
components” so long as there are “no clinically meaningful differences between the biological product
and the reference product in terms of safety, purity, and potency”).
158 SCIENTIFIC CONSIDERATIONS IN DEMONSTRATING BIOSIMILARITY, supra note 44, at 20.
159 See Gaudry, supra note 156, at 619–20.
160 See Smithkline Beecham Corp. v. Apotex Corp., 439 F.3d 1312, 1315 (Fed. Cir. 2006)
(defining a product-by-process claim as one that defines a product based on the method or process by
which it is made); FED. TRADE COMM’N, EMERGING HEALTH CARE ISSUES: FOLLOW-ON BIOLOGIC
DRUG COMPETITION 31 (2009), available at http://www.ftc.gov/os/2009/06/P083901biologicsreport.pdf
(listing several types of claims appropriate for biologics).
161 See Hilton Davis Chem. Co. v. Warner-Jenkinson Co., 62 F.3d 1512, 1536 (Fed. Cir. 1995)
(en banc) (Newman, J., concurring) (“[T]he patent law[s] place[] strong pressure on filing the patent
application early in the development of the technology, often before the commercial embodiment is
developed or all the boundaries fully explored.”), rev’d on other grounds, 520 U.S. 17 (1997).
162 Decaire et al., supra note 150, at 1058.
156
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make characterizing it difficult, even with the passage of more time. 163 In certain
instances, functional language may be appropriately utilized to maximize claim
scope. For example, the function of a substance may be more definite than its
structure.
Whether or not functional language is appropriate and utilized,
preserving equivalents can better position biologics producers, as such elements
might cover a biosimilar or other BLA product. 164
When implementing these and other strategies, a subset of considerations for at
least a set of claims should focus on the specific biosimilar pathway requirements.
For example, focusing on potency, purity, and safety parameters may each be
valuable. Further, the current FDA draft guidelines recommend a “stepwise
approach” that compares the biosimilar to the reference product with respect to
several factors.165 Concentrating on these factors may provide guidance on claiming
strategies.
Exemplary factors may include function, effectiveness, human
pharmacokinetics, human pharmacodynamics, clinical immunogenicity, and related
parameter.166 Therefore, it would likely be beneficial to draft claims directed towards
these parameters of the reference product, as well as methods of testing.
III. RESOLVING PATENT DISPUTES
A. Introduction
Given the unrelated (but intertwined) nature of the Biosimilar Act’s exclusivities
and the U.S Patent Law’s exclusionary rights, there will undoubtedly be patent
disputes. For example, Innovators are likely to have patent coverage towards their
innovator biologic products. Highly marketable innovator biologics will undoubtedly
serve as a reference product for a biosimilar applicant’s product. Thus, the
Innovator’s first reaction will be to determine whether its patent rights are infringed
by the biosimilar product. Equally likely are situations in which biosimilar
applicants contend that such patent rights are either not infringed by their products
(or processes related to the manufacturing or testing of the product) or such rights
are invalid for one or more reasons. Further, biosimilar applicants, themselves, may
have patent rights that may be enforced against the Innovator. Fortunately, the
Biosimilar Act anticipated such situations and has provisions that provide an avenue
for resolving patent disputes.

163 See Daron I. Freedberg, Improvement of Biological Product Quality by Application of New
Technologies to Characterize of Vaccines and Blood Products:
NMR Spectroscopy and Light
Scattering, FOOD & DRUG ADMIN., http://www.fda.gov/biologicsbloodvaccines/scienceresearch/
biologicsresearchareas/ucm127270.htm (last visited Feb. 17, 2013).
164 See supra notes 156 and 160.
165 See supra Part I.C.3.a.i.
166 See supra note 45 and accompanying text.
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B. Triggering of the Patent Dispute Provisions
As a preliminary matter, it is worth noting that pre-clinical and clinical
investigation in preparation of regulatory filing is exempt from infringement. 167 This
is another similarity to the European system, which also exempts pre-clinical and
clinical investigations conducted in preparation for regulatory filings.168 In the EU,
however, the actual filing of the Marketing Authorization Application for a biosimilar
product is not constructive infringement.169 In the United States, the Act renders
such actions constructive infringement.170
The Act sets forth the process that the parties must undergo in the event of any
patent disputes.171 The Act ensures that Innovators of the reference product are
aware of any 351(k) filings.172 Specifically, a biosimilar applicant must provide its
application, inclusive of details on the manufacturing process, to the Innovator of the
reference product within twenty days of the FDA’s acceptance for review.173 The
application is provided under confidentiality.174 The Innovator then has sixty days
to provide an initial list of patents that could reasonably be asserted against the
biosimilar application.175 As part of this process, the Innovator may optionally
choose to designate patents that are available for license.176
Within sixty days of receiving the initial list of the patents from the Innovator,
the biosimilar applicant has the opportunity to provide an initial list of patents that
it contends could reasonably be asserted by the Innovator.177 For each patent that
could be asserted, the biosimilar applicant can either (1) provide the Innovator with a
claim chart identifying facts and law supporting invalidity, unenforceability, or noninfringement, or (2) provide a statement that the biosimilar applicant does not intend
to begin marketing its product prior to the patent’s expiration.178 The biosimilar
applicant also has the opportunity, here, to respond to the Innovator’s list of patents
available for licensing.179 If the biosimilar applicant filed any allegations regarding
non-infringement, invalidity, or unenforceability of the patents-at-issue, the
Innovator has sixty days to provide rebuttals to such allegations.180 Figure 1
provides a timeline of the relevant dates of the patent dispute provisions.

35 U.S.C. § 271(e)(1) (2012).
See Patents Act, 1977, c. 37, § 60(5) (U.K.).
169 See Loeb, supra note 140 (comparing U.S. and European biosimilar regulation and
litigation).
170 35 U.S.C. § 271(e)(2)(C).
171 42 U.S.C. § 262(l)(4)–(7).
172 See, e.g., id. § 262(l)(3) (requiring subsection (k) applicants and reference product sponsors
to exchange lists of patents implicated).
173 Id. § 262(l)(2).
174 Id. § 262(l)(1)(B).
175 Id. § 262(l)(3)(A)(i).
176 Id. § 262(l)(3)(A)(ii).
177 Id. § 262(l)(3)(B)(i).
178 Id. § 262(l)(3)(B)(ii).
179 Id. § 262(l)(3)(B)(i).
180 Id. § 262(l)(3)(C).
167
168
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Figure 1. Timeline of the Patent Dispute Provisions

C. Negotiating the Basis for an Infringement Action
At this point, the parties have fifteen days to negotiate a list of patents to form
the basis for an infringement action.181 The Act contemplates the fact that some
negotiations are likely to be more contentious than others and, as such, recognizes
that the parties may not reach an agreement. 182 If there is not an agreement, then
the Act’s patent exchange procedures are triggered in which a biosimilar applicant
identifies the number of patents it will exchange.183 Under this scenario, the
biosimilar applicant controls the number of patents in an infringement action. 184
Specifically, the Innovator cannot list a number of patents greater than the number
identified by the biosimilar applicant.185 An exception exists when the biosimilar
applicant identifies zero patents in which the Innovator can list one patent. 186
Within five days, the parties simultaneously exchange lists of patents.187 The
Innovator then has thirty days to bring an infringement action for each patent on
both lists.188
Alternatively, if the parties negotiate a list of patents to form the basis for an
infringement action, the Innovator has the thirty days to bring an infringement
action for each of the negotiated patents.189 Upon filing of the patent infringement
action, the biosimilar applicant provides notice to the FDA, and the FDA publishes
notice of complaint in the Federal Register.190 The FDA does not suspend review of
Id. § 262(l)(4)(B).
Id.
183 Id. § 262(l)(5)(B)(i).
184 Id.
185 Id. § 262(l)(5)(B)(ii)(I).
186 Id. § 262(l)(5)(B)(ii)(II).
187 Id. § 262(l)(5)(B)(i)(I).
188 Id. § 262(l)(6)(B).
189 Id. § 262(l)(6)(A).
190 Id. § 262(l)(6)(C).
181
182
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the abbreviated application as a result of a potential patent dispute. 191 This is unlike
the Hatch-Waxman Act in which the Innovator must list their patents in the Orange
Book, and the FDA review is suspended for thirty months if an Innovator files suit. 192
1. Preliminary Injunction Procedures
The Act further contemplates that a patent may issue after the Innovator
provides its initial list of patents. 193 For patents that are issued or licensed after the
Innovator identifies its initial list, the Innovator will supplement the initial list with
the additional patents within thirty days.194 The biosimilar applicant then has thirty
days to provide a position on non-infringement, invalidity, or unenforceability.195 It
should be noted, however, that these patents are not part of the negotiated/exchange
procedures, but are instead subject to Preliminary Injunction procedures.
The Act requires that the biosimilar applicant provide the Innovator with a 180day notice of intent to market.196 The Innovator may seek a preliminary injunction
(“PI”) on any patents on any lists. 197 The biosimilar applicant must reasonably
cooperate to expedite discovery in any infringement action by the Innovator seeking
PI.198
2. Declaratory Judgments
With respect to seeking a declaratory judgment (“DJ”), the Act limits a DJ
action.199 In particular, if the Innovator had confidential access to the biosimilar
application, neither party can bring a DJ action before the 180-day notice of
commercial marketing is received.200 Moreover, DJ actions can only be brought
against patents for which a PI motion has been filed.201 Importantly, if the biosimilar
applicant fails to respond during the process described above, the Innovator can
bring a DJ action on any patent on the Innovator’s initial list and list of newly
issued/licensed patents.202 If the biosimilar applicant fails to provide access to
confidential information during the patent dispute process, the Innovator can bring a
DJ action on any patent that claims the biological product or its use, but not that
claims manufacture of the biological product.203
191 See Lisa H. Wang, Biosimilar Act Differs from Hatch-Waxman in Several Key Ways,
GIBBONS LAW (Aug. 16, 2010), http://www.gibbonslaw.com/UserFiles/Image/1288801911.pdf.
192 See 21 C.F.R. § 314.107(b)(3)(i)(A) (2013).
193 42 U.S.C. § 262(l)(7) (2012).
194 Id.
195 Id.
196 Id. § 262(l)(8)(A).
197 Id. § 262(l)(8)(B).
198 Id. § 262(l)(8)(C).
199 Id. § 262(l)(9).
200 Id. § 262(l)(9)(A).
201 Id.
202 Id. § 262(l)(9)(B).
203 Id. § 262(l)(9)(C).
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CONCLUSIONS
In view of the patent dispute provisions of the Act, an Innovator should make
sure to identify ALL of the patents that are a potential interest for litigation because,
if any are left off of the list and the biosimilar applicant does not identify them, then
the Innovator cannot sue on such patents prior to launch.204 The only exception
would be in the situation where the biosimilar applicant fails to provide confidential
access during the patent dispute process.205 Patents identified on negotiated or
exchanged lists, however, can be litigated immediately.206 Patents on the Innovator’s
initial list, but not on negotiated or exchanged lists, cannot be litigated until a 180day marketing notice is provided.

Id. § 262(l)(6)(A).
Id. § 262(l)(9)(C).
206 Id. § 262(l)(9)(A)–(B).
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